.jpg)
耀杰不凡丨第三刊：流感樣病例獲關(guān)注，新冠與呼吸道病原鑒別成關(guān)鍵！
新冠肺炎（COVID-19）疫情橫掃全球已有1年，國內(nèi)已完全得到控制，而國外疫情發(fā)展依舊撲朔迷離，
“耀杰不凡”致敬幕后抗疫英雄推文解讀活動
第三刊：流感樣病例獲關(guān)注，新冠與呼吸道病原鑒別成關(guān)鍵！
本期分享的內(nèi)容正是武漢疾控中心病原生物檢驗所副所長劉滿清所帶領(lǐng)的團(tuán)隊做出的成果，研究重新分析了2019年10月6日至2020年1月21日在武漢市收集的640份流感樣病例的咽拭子檢測結(jié)果。團(tuán)隊通過使用上海伯杰醫(yī)療的新冠檢測試劑，檢測出了9例新冠陽性病例。經(jīng)綜合分析知，在2020年1月上旬，新冠已經(jīng)在武漢社區(qū)內(nèi)傳播，并且這些病人混合在流感樣病例當(dāng)中。
參考文獻(xiàn)：
1. Coronavirus Disease 2019 (COVID-19) Situation Report 33 (World Health Organization, 2020).
2. Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
3. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of
probable bat origin. Nature 579, 270–273 (2020).
4. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China,
2019. N. Engl. J. Med. 382, 727–733 (2020).
5. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
6. Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523 (2020).
7. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly 2, 113–122 (2020).
8. Epidemic Update and Risk Assessment of 2019 Novel Coronavirus (Chinese Center for Disease Control and Prevention, 2020).
9. Yang, P. et al. Review of an influenza surveillance system, Beijing, People’s Republic of China. Emerg. Infect. Dis. 15, 1603–1608 (2009).
10. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).
11. Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel
coronavirus-infected pneumonia. N. Engl. J. Med. 323, 1199–1207 (2020).
12. Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395, 689–697 (2020).
13. Li, L. & Fu, H. China’s health care system reform: progress and prospects.
Int. J. Health Plann. Manage. 32, 240–253 (2017).
14. Wang, M. et al. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. Preprint at medRxiv https://doi. org/10.1101/2020.02.12.20022327 (2020).
15. Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of
infected patients. N. Engl. J. Med. 382, 1177–1179 (2020).
16. Shi, W. et al. Co-circulation and persistence of multiple A/H3N2 influenza
variants in China. Emerg. Microbes Infect. 8, 1157–1167 (2019).
17. Peng, J. et al. The epidemiology and etiology of influenza-like illness in Chinese children from 2008 to 2010. J. Med. Virol. 84, 672–678 (2012).
上海伯杰醫(yī)療科技有限公司是一家致力于感染性病原體分子診斷試劑研發(fā)和應(yīng)用，深耕于多重?zé)晒釶CR診斷試劑和痕量病毒二代測序試劑及相關(guān)服務(wù)的國家高新技術(shù)企業(yè)。公司圍繞感染性病原體這一主線，從診斷試劑、診斷儀器、測序服務(wù)和醫(yī)檢所服務(wù)等多個面提供全套解決方案。公司秉承“勇于創(chuàng)新，質(zhì)量為先”的方針，為醫(yī)療機(jī)構(gòu)、疾控公衛(wèi)、高校科研等合作伙伴提供優(yōu)質(zhì)產(chǎn)品與服務(wù)。
全國客服電話：400-860-3688